DE68925594T2 - Liganden und ihre Komplexe mit Technetium-99m - Google Patents
Liganden und ihre Komplexe mit Technetium-99mInfo
- Publication number
- DE68925594T2 DE68925594T2 DE68925594T DE68925594T DE68925594T2 DE 68925594 T2 DE68925594 T2 DE 68925594T2 DE 68925594 T DE68925594 T DE 68925594T DE 68925594 T DE68925594 T DE 68925594T DE 68925594 T2 DE68925594 T2 DE 68925594T2
- Authority
- DE
- Germany
- Prior art keywords
- ligand
- formula
- groups
- ligands
- phosphorus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 36
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 title claims abstract description 7
- 229940056501 technetium 99m Drugs 0.000 title claims abstract description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 12
- 239000011574 phosphorus Substances 0.000 claims abstract description 12
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical group [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052785 arsenic Chemical group 0.000 claims abstract description 6
- 125000002091 cationic group Chemical group 0.000 claims abstract description 6
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 4
- 230000002107 myocardial effect Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229910052713 technetium Inorganic materials 0.000 description 4
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 4
- CVKJXWOUXWRRJT-UHFFFAOYSA-N technetium dioxide Chemical group O=[Tc]=O CVKJXWOUXWRRJT-UHFFFAOYSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FWFZRPMNAAFGBA-UHFFFAOYSA-N 2-phosphanylethylphosphane Chemical compound PCCP FWFZRPMNAAFGBA-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- -1 Allylic ethers Chemical class 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- WCHFOOKTKZYYAE-UHFFFAOYSA-N ethoxyperoxyethane Chemical group CCOOOCC WCHFOOKTKZYYAE-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/20—Esters of thiophosphoric acids containing P-halide groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5027—Polyphosphines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888808414A GB8808414D0 (en) | 1988-04-11 | 1988-04-11 | Ligands & cationic complexes thereof with technetium-99m |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE68925594D1 DE68925594D1 (de) | 1996-03-21 |
| DE68925594T2 true DE68925594T2 (de) | 1996-06-20 |
Family
ID=10634927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE68925594T Expired - Lifetime DE68925594T2 (de) | 1988-04-11 | 1989-04-05 | Liganden und ihre Komplexe mit Technetium-99m |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5045302A (enExample) |
| EP (1) | EP0337654B1 (enExample) |
| JP (2) | JP2690142B2 (enExample) |
| KR (1) | KR0149439B1 (enExample) |
| CN (2) | CN1022633C (enExample) |
| AT (1) | ATE133956T1 (enExample) |
| CA (1) | CA1336437C (enExample) |
| DE (1) | DE68925594T2 (enExample) |
| DK (1) | DK171416B1 (enExample) |
| ES (1) | ES2082771T3 (enExample) |
| GB (1) | GB8808414D0 (enExample) |
| HK (1) | HK98097A (enExample) |
| IL (1) | IL89779A (enExample) |
| TW (1) | TW206231B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD291327A5 (de) * | 1989-12-29 | 1991-06-27 | �������@����@�K@��@��k�� | Myokardgaengige technetium-komplexverbindungen und verfahren zu deren herstellung |
| US5338864A (en) * | 1992-07-06 | 1994-08-16 | Mallinckrodt Medical, Inc. | Hexadentate ligands useful in radiographic imaging agents |
| US5744120A (en) * | 1993-03-30 | 1998-04-28 | The Dupont Merick Pharmaceutical Company | Ternary radiopharmaceutical complexes |
| US5750088A (en) * | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
| US7575653B2 (en) * | 1993-04-15 | 2009-08-18 | 3M Innovative Properties Company | Melt-flowable materials and method of sealing surfaces |
| WO1996030056A1 (en) * | 1995-03-29 | 1996-10-03 | The Curators Of The University Of Missouri | Hydroxyalkyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals and method of making same |
| AU6231699A (en) * | 1998-09-30 | 2000-04-17 | Atofina Vlissingen B.V. | Fluorous phosphines and processes for their preparation |
| GB0427392D0 (en) * | 2004-12-15 | 2005-01-19 | Amersham Plc | Stabilised 99mTc compositions |
| JP4863345B2 (ja) * | 2005-03-18 | 2012-01-25 | 国立大学法人金沢大学 | 心筋用放射性画像診断剤又は放射性治療薬 |
| CA2654369C (en) * | 2006-06-21 | 2014-10-14 | Ge Healthcare Limited | Radiopharmaceutical products |
| JP5427483B2 (ja) * | 2009-06-19 | 2014-02-26 | 株式会社化研 | 放射性医薬品およびその標識化合物原料としての放射性テクネチウムの濃縮および溶出回収方法、およびシステム |
| US9321095B2 (en) | 2010-06-30 | 2016-04-26 | General Electric Company | Apparatuses and methods for cutting porous substrates |
| EP2899195A1 (en) | 2014-01-28 | 2015-07-29 | ROTOP Pharmaka AG | Stabilized form of Tetrofosmin and its use |
| US10836781B2 (en) * | 2017-03-08 | 2020-11-17 | Jubilant Generics Limited | Process for the preparation of tetrofosmin or acid salt thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2005790A1 (en) * | 1968-04-08 | 1969-12-19 | Toa Gosei Chemical Indus | But-1-ene-2,3,4-tricarboxylic ester is prepared by reacting acrylic ester with maleic or fumaric ester in presence of phosphine-type catalyst. New cpds. a |
| US4451450A (en) * | 1981-10-15 | 1984-05-29 | New England Nuclear Corporation | Cationic compounds useful for making radiodiagnostic agents |
| US4481184A (en) * | 1983-02-14 | 1984-11-06 | E. R. Squibb & Sons, Inc. | Cationic technetium (I) complexes |
| US4526776A (en) * | 1983-04-15 | 1985-07-02 | E. I. Du Pont De Nemours & Company | Cationic cyanato and thiocyanato complexes useful as radiodiagnostic agents |
| GB8723438D0 (en) * | 1987-10-06 | 1987-11-11 | Amersham Int Plc | Cationic complexes of technetium-99m |
| JP3176489B2 (ja) * | 1993-07-22 | 2001-06-18 | 中部電力株式会社 | 真空バルブ |
-
1988
- 1988-04-11 GB GB888808414A patent/GB8808414D0/en active Pending
-
1989
- 1989-03-28 IL IL8977989A patent/IL89779A/en unknown
- 1989-03-28 US US07/329,639 patent/US5045302A/en not_active Expired - Lifetime
- 1989-04-01 TW TW078102489A patent/TW206231B/zh active
- 1989-04-05 JP JP1086711A patent/JP2690142B2/ja not_active Expired - Lifetime
- 1989-04-05 DK DK163289A patent/DK171416B1/da not_active IP Right Cessation
- 1989-04-05 AT AT89303374T patent/ATE133956T1/de not_active IP Right Cessation
- 1989-04-05 CA CA000595715A patent/CA1336437C/en not_active Expired - Lifetime
- 1989-04-05 ES ES89303374T patent/ES2082771T3/es not_active Expired - Lifetime
- 1989-04-05 EP EP89303374A patent/EP0337654B1/en not_active Expired - Lifetime
- 1989-04-05 DE DE68925594T patent/DE68925594T2/de not_active Expired - Lifetime
- 1989-04-06 KR KR1019890004588A patent/KR0149439B1/ko not_active Expired - Lifetime
- 1989-04-06 CN CN89102600A patent/CN1022633C/zh not_active Expired - Lifetime
-
1993
- 1993-02-23 CN CN93102336A patent/CN1031828C/zh not_active Expired - Lifetime
-
1997
- 1997-02-28 JP JP9046316A patent/JP2764037B2/ja not_active Expired - Lifetime
- 1997-06-26 HK HK98097A patent/HK98097A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK98097A (en) | 1997-08-08 |
| KR0149439B1 (ko) | 1998-10-15 |
| EP0337654A3 (en) | 1991-04-24 |
| JPH09328495A (ja) | 1997-12-22 |
| GB8808414D0 (en) | 1988-05-11 |
| DK163289D0 (da) | 1989-04-05 |
| CA1336437C (en) | 1995-07-25 |
| CN1040373A (zh) | 1990-03-14 |
| EP0337654A2 (en) | 1989-10-18 |
| CN1022633C (zh) | 1993-11-03 |
| CN1031828C (zh) | 1996-05-22 |
| IL89779A (en) | 1995-01-24 |
| TW206231B (enExample) | 1993-05-21 |
| ES2082771T3 (es) | 1996-04-01 |
| ATE133956T1 (de) | 1996-02-15 |
| KR900016237A (ko) | 1990-11-13 |
| US5045302A (en) | 1991-09-03 |
| IL89779A0 (en) | 1989-09-28 |
| JP2764037B2 (ja) | 1998-06-11 |
| CN1079746A (zh) | 1993-12-22 |
| DE68925594D1 (de) | 1996-03-21 |
| DK163289A (da) | 1989-10-12 |
| EP0337654B1 (en) | 1996-02-07 |
| DK171416B1 (da) | 1996-10-21 |
| JP2690142B2 (ja) | 1997-12-10 |
| JPH0222286A (ja) | 1990-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68925594T2 (de) | Liganden und ihre Komplexe mit Technetium-99m | |
| DE68928705T2 (de) | Technetium-99m-komplex zur untersuchung der nierenfunktion | |
| DE69331203T2 (de) | Kontrastzusammensetzungen für kernmagnetische Resonanz | |
| DE112018003015B4 (de) | 99mTc-MARKIERTES ISONITRIL-ENTHALTENDES GLUCOSEDERIVAT UND HERSTELLUNGSVERFAHREN UND VERWENDUNG DAVON | |
| DE69432418T2 (de) | Phosphonate- und nicht-phosphonate einheiten enthaltende polyamino-paramagnetische-chelate fuer anwendung in mri | |
| DE69101708T2 (de) | Verfahren zur herstellung von übergangsmetallnitridkomplexen. | |
| DE69131850T2 (de) | Technetium-99m-komplexe zur verwendung als radiopharmazeutische mittel | |
| DE4311023C2 (de) | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel | |
| DE69116637T2 (de) | Mittel zur magnetischen Resonanzabbildung | |
| DE68909245T2 (de) | Übergangsmetall-stickstoffkomplex enthaltendes radiopharmazeutisches produkt mit einer neigung zum herzgewebe. | |
| US4916214A (en) | Cationic complexes of technetium-99m | |
| DE2947500C2 (de) | Radiojodierte ω -Phenylfettsäuren, ihre Herstellung und deren Verwendung zur szintigraphischen Untersuchung des Herzmuskels und der Leber | |
| DE69231811T2 (de) | Uebergangsmetall-Nitridokomplex enthaltendes Radiopharmazeutisches Produkt mit einer Neigung zum Gehirn, Verfahren zu deren Herstellung | |
| DE69721820T2 (de) | Nitrid-heterokomplexe von radioaktiven übergangsmetallen | |
| DE69130982T2 (de) | Technetiumkomplex für die bestimmung der nierenfunktion | |
| LU85042A1 (de) | Verfahren zur abbildung des myokard von saeugetieren | |
| DE69003277T2 (de) | Kationische Komplexe von Technetium-99m und Liganden dafür. | |
| DE3852828T2 (de) | Tris(isonitrile)kupfer(i)-addukte zur herstellung von radionuklid-komplexen. | |
| DE69118520T2 (de) | Sechsbindige liganden für radiographische abbildungsagenzien | |
| DE3633243A1 (de) | Phosphonat-komplexe | |
| DE69603617T2 (de) | Phosphorhaltige cytisin-derivate | |
| DE69620762T2 (de) | Cardiotropische radiopharmazeutika,die einen übergangsmetall-nitrid-komplex enthalten und die eine rasche myocardial-eliminierung aufweisen | |
| DE4311022C2 (de) | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel | |
| DE69421173T2 (de) | Neue stickstoff-schwefel-liganden auf der basis eines heterocyclus für die verwendung in werkstoffen für die radiographische bildgebung | |
| Rau et al. | Inhibitoren der Nucleosidphosphorylierung in vivo/Inhibitors of Nucleoside Phosphorylation in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: HAMMONDS RECHTSANWAELTE PATENTANWAELTE, 80539 MUENCHEN |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: GE HEALTHCARE LTD., LITTLE CHALFONT, BUCKINGHAMSHI |